FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Jörg Engel

Research Profile

Anatomy

Tumor Cell Line

Chemicals & Drugs

Living Beings

Disorders

Procedures

Physiology

Pregnancy

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Jens Claus Hahne; Johannes Dietl; Jörg Engel; Susanne R Meyer; Heike Schmidt; Arnd Honig
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
Jens Claus Hahne; Johannes Dietl; Jörg Engel; Stepan Gambaryan; Susanne R Meyer; Ulrich Walter; Arnd Honig
Immune escape of AKT overexpressing ovarian cancer cells.
Mathias Krockenberger; Katharina Nürnberger; Jörg Wischhusen; Evi Horn; Peter Kranke; Johannes Dietl; Jörg Engel; Sebastian Häusler; Arnd Hönig
Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Jörg Engel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Jens Claus Hahne; Johannes Dietl; Jörg Engel; Susanne R Meyer; Heike Schmidt; Arnd Honig
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
Journal of cancer research and clinical oncology 2013;139(6):905-14.
2013: Jens Claus Hahne; Johannes Dietl; Jörg Engel; Stepan Gambaryan; Susanne R Meyer; Ulrich Walter; Arnd Honig
Immune escape of AKT overexpressing ovarian cancer cells.
International journal of oncology 2013;42(5):1630-5.
2012: Mathias Krockenberger; Katharina Nürnberger; Jörg Wischhusen; Evi Horn; Peter Kranke; Johannes Dietl; Jörg Engel; Sebastian Häusler; Arnd Hönig
Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis.
Anticancer research 2012;32(12):5233-8.
2012: Jens Claus Hahne; S F M Häussler; Arnd Honig; Susanne R Meyer; Sabine Elisabeth Segerer; U Walter; Jörg Wischhusen; Johannes Dietl; N Fujita; S Gambaryan; Jörg Engel
Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Oncology reports 2012;28(6):2023-8.
2012: Jörg Engel; Stefan Buchholz; Günter Emons; Andrew V Schally; S Seitz; Olaf Ortmann
Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Archives of gynecology and obstetrics 2012;286(2):437-42.
2012: Jörg Engel; Jens Claus Hahne; S F M Häusler; J Diessner; Johannes Dietl; S Meyer; Sabine Elisabeth Segerer; Arnd Honig
Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
Anticancer research 2012;32(5):2063-8.
2012: Arnd Honig; P Kranke; S Meyer; J Diessner; Johannes Dietl; Jens Claus Hahne; S Häusler; Jörg Engel
PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.
Anticancer research 2012;32(5):2035-41.
2012: Jörg Engel; Jens C Hahne; Sebastian F M Häusler; Mathias Krockenberger; Theresa Martens; Susanne Meyer; Sabine Segerer; Jörg Wischhusen; Johannes Dietl; Antonia Djakovic; Arnd Honig
Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
Anti-cancer drugs 2012;23(4):426-36.
2011: Jörg Engel; S F M Häusler; Arnd Hönig; M Rehn; Johannes Dietl; A Djakovic
[Late interruption of pregnancy due to foetal disease: is an inductive method for the generation of ethical principles applicable?].
Zeitschrift für Geburtshilfe und Neonatologie 2011;215(6):230-3.
2011: J Diessner; Johannes Dietl; Jörg Engel; T Frambach; S Heuer; P Kranke; C Quaisser; A Honig
[Myocardial infarction in the 34th week of gestation: case report].
Zeitschrift für Geburtshilfe und Neonatologie 2011;215(5):209-11.
2011: Sebastian F M Häusler; Stefan Heuer; Arnd Hönig; Evi Horn; Markus Junker; Doris Kloor; Karl-Norbert Klotz; Hermann Kneitz; Mathias Krockenberger; Itsaso Montalbán del Barrio; Monika Ossadnik; Ahmed Adel Seida; Jenny Strohschein; P Anoop Chandran; Johannes Dietl; Jörg Engel; Birgitt Fischer; Jörg Wischhusen
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Cancer immunology, immunotherapy : CII 2011;60(10):1405-18.
2011: Jörg Engel; Stefan Heuer; Sabine Segerer; Stephan Rauthe; Johannes Dietl; Arnd Hönig
Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer--Occam's razor or the "third man".
Fertility and sterility 2011;95(5):1787.e5-7.
2011: Jörg Engel; Tanja Schönhals; Sebastian Häusler; Mathias Krockenberger; Melanie Schmidt; Evi Horn; Frank Köster; Johannes Dietl; Jörg Wischhusen; Arnd Honig
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Archives of gynecology and obstetrics 2011;283(3):603-10.
2011: A Djakovic; Jörg Engel; E Geisinger; Arnd Honig; Alexander Tschammler; Johannes Dietl
Pleomorphic adenoma of the breast initially misdiagnosed as metaplastic carcinoma in preoperative stereotactic biopsy: a case report and review of the literature.
European journal of gynaecological oncology 2011;32(4):427-30.
2011: Andrew V Schally; Jörg Engel; Gunter Emons; Norman Block; Jacek Pinski
Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.
Current drug delivery 2011;8(1):11-25.
2010: Jörg Engel; Arnd Hönig; S Segerer; S F M Häusler; Johannes Dietl; A Djakovic
The moral status of the embryo: an attempt at an analysis with the aid of David Hume's ethics.
Reproductive biomedicine online 2010;21(7):830-3.
2010: Arnd Honig; Jörg Engel; Sabine Elisabeth Segerer; Peter Kranke; Sebastian Häusler; Wolfgang Würfel
Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.
Human reproduction (Oxford, England) 2010;25(11):2753-4.
2010: S F M Häusler; A Keller; P A Chandran; K Ziegler; K Zipp; S Heuer; M Krockenberger; Jörg Engel; Arnd Hönig; M Scheffler; Johannes Dietl; Jörg Wischhusen
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.
British journal of cancer 2010;103(5):693-700.
2010: Arnd Honig; C Weidler; S Häusler; M Krockenberger; Stefan Buchholz; F Köster; Sabine Elisabeth Segerer; Johannes Dietl; Jörg Engel
Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer.
Anticancer research 2010;30(5):1559-64.
2009: Stefan Buchholz; Stephan Seitz; Andrew V Schally; Jörg Engel; Ferenc Rick; Luca Szalontay; Florian Hohla; AWTAR KRISHAN; Andrea Papadia; Timo Gaiser; Gero Brockhoff; Olaf Ortmann; Klaus Diedrich; Frank Köster
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
International journal of oncology 2009;35(4):789-96.
2009: Jörg Engel; Tanja Schönhals; Claudia Weidler; Sebastian Häusler; Mathias Krockenberger; Lorenz Rieger; Johannes Dietl; Jörg Wischhusen; Arnd Honig
Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition.
Oncology reports 2009;22(2):361-7.
2009: Frank Köster; Jörg Engel; Andrew V Schally; Arnd Hönig; Andreas Schröer; Stephan Seitz; Florian Hohla; Olaf Ortmann; Klaus Diedrich; Stefan Buchholz
Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Breast cancer research and treatment 2009;116(2):273-9.
2009: M Krockenberger; Jörg Engel; S Häusler; Johannes Dietl; Arnd Honig
Prolonged clinical benefit from platinum-based chemotherapy in a patient with metastatic triple negative breast cancer.
European journal of gynaecological oncology 2009;30(4):449-51.
2008: Stephan Seitz; Florian Hohla; Andrew V Schally; Angelika Moder; Jörg Engel; Felicitas Horn; Jozsef Varga; Marta Zarandi; Olaf Ortmann; Frank Köster; Stefan Buchholz
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Oncology reports 2008;20(5):1289-94.
2008: Jörg Engel; Arnd Honig; Tanja Schönhals; Claudia Weidler; Sebastian Häusler; Mathias Krockenberger; Thomas Grunewald; Yvonne Dombrowski; Lorenz Rieger; Johannes Dietl; Jörg Wischhusen
Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
European journal of obstetrics, gynecology, and reproductive biology 2008;141(1):64-9.
2008: Andrew V Schally; Jozsef Varga; Jörg Engel
Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Nature clinical practice. Endocrinology & metabolism 2008;4(1):33-43.
2007: Jörg Engel; Alain Audebert; René Frydman; Jaroslav Zivny; Klaus Diedrich
Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study.
European journal of obstetrics, gynecology, and reproductive biology 2007;134(2):225-32.
2007: Jörg Engel; Andrew V Schally; Johannes Dietl; Lorenz Rieger; Arnd Hönig
Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
Molecular pharmaceutics 2007;4(5):652-8.
2007: Johannes Dietl; Jörg Engel; Jörg Wischhusen
The role of regulatory T cells in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):764-70.
2007: Stefan Buchholz; Andrew V Schally; Jörg Engel; Florian Hohla; Elmar Heinrich; Frank Koester; Jozsef Varga; Gabor Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(6):1943-6.
2007: Jörg Engel; Andrew V Schally
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
Nature clinical practice. Endocrinology & metabolism 2007;3(2):157-67.
2006: Stefan Buchholz; Gunhild Keller; Andrew V Schally; Gabor Halmos; Florian Hohla; Elmar Heinrich; Frank Koester; Ben Baker; Jörg Engel
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10403-7.
2006: Jörg Engel; Georg Griesinger; Askan Schultze-Mosgau; Ricardo Felberbaum; K Diedrich
GnRH agonists and antagonists in assisted reproduction: pregnancy rate.
Reproductive biomedicine online 2006;13(1):84-7.
2006: Gunhild Keller; Andrew V Schally; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
International journal of oncology 2006;28(6):1507-13.
2006: Timo Gaiser; Josef Rüschoff; Andrew V Schally; Gunhild Keller; Jörg Engel
[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues].
Verhandlungen der Deutschen Gesellschaft für Pathologie 2006;90():186-92.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocrine-related cancer 2005;12(4):999-1009.
2005: Gunhild Keller; Andrew V Schally; Attila Nagy; Gabor Halmos; Ben Baker; Jörg Engel
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer 2005;104(10):2266-74.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer 2005;104(6):1312-21.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2196-202.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5549-57.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1824-30.
2005: Gunhild Keller; Andrew V Schally; Kate Groot; Gabor L Toller; Alexandre Havt; Frank Köster; Patricia Armatis; Gabor Halmos; Marta Zarandi; Jozsef Varga; Jörg Engel
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10628-33.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabriela Westphal; Gabor Halmos; Jörg Engel
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer research 2005;65(13):5857-63.
2005: Jörg Engel; Askan Schultze-Mosgau; Klaus Diedrich
Five years' clinical use of GnRH antagonists: evaluation of safety and allergic potential.
Reproductive biomedicine online 2005;10 Suppl 3():61-5.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Gabor L Toller; Kate Groot; Alexandre Havt; Patricia Armatis; Marta Zarandi; Jozsef Varga; Gabor Halmos
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
The Journal of clinical endocrinology and metabolism 2005;90(6):3614-21.
2005: Gunhild Keller; Jörg Engel; Andrew V Schally; Attila Nagy; Brian D Hammann; Gabor Halmos
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
International journal of cancer. Journal international du cancer 2005;114(5):831-5.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Attila Nagy; David D Chism; Gabor Halmos
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertility and sterility 2005;83 Suppl 1():1125-33.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Gabor Halmos; Brian D Hammann; Attila Nagy
Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2408-15.
2005: Jörg Engel; H Riethmüller-Winzen; Klaus Diedrich
Extrapituitary effects of GnRH antagonists in assisted reproduction: a review.
Reproductive biomedicine online 2005;10(2):230-4.
2003: Jörg Engel; Ricardo Felberbaum; Klaus Junge; Thomas Reissmann; Klaus Diedrich
Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.
Archives of gynecology and obstetrics 2003;268(4):278-80.
2003: Jörg Engel; Michael Ludwig; K Junge; COLIN MICHAEL HOWLES; Klaus Diedrich
No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols.
Reproductive biomedicine online 2003;6(4):482-7.
2003: Jörg Engel; François Olivennes; Renato Fanchin; Frydman Nelly; Anne Le Dû; V Blanchet; René Frydman
Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study.
Reproductive biomedicine online 2003;6(4):444-7.
2002: Jörg Engel; Ricardo Felberbaum; Wiebke Eilers; Stephan Polack; Olaf Ortmann; Klaus Diedrich
Clomiphene-induced LH surges and cetrorelix.
Reproductive biomedicine online 2002;5(2):109-11.
2002: Jörg Engel; Michael Ludwig; Ricardo Felberbaum; C Albano; P Devroey; Klaus Diedrich
Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?
Human reproduction (Oxford, England) 2002;17(8):2022-6.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.